Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial

EHA 2026

Leukemia

CLL13/GAIA: Final 5-year analysis identifies NOTCH1 and EGR2 mutations as independent prognostic factors in venetoclax-treated CLL

EHA 2026

Leukemia

CLL14: Final 9-year analysis confirms long-term efficacy of one-year fixed-duration venetoclax plus obinutuzumab in previously untreated CLL

Genitourinary Cancer

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial

Eur Urol

Cooper S, Patel J, Moore C, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Camilleri P, Kancherla K, Frew J, Chan A, Naismith O, Armstrong J, Staffurth J, Martin A, Dayes I, Wells P, Price D, Pugh J, Manning G, Brown S, Burnett S, van As N, Hall E, Tree AC

doi: 10.1016/j.eururo.2026.05.034

SPECIAL REPORT

Genitourinary Cancer

Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes

Lung, Respiratory and Thoracic Cancer

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial

Lancet Oncol

Hassing MJ, Billingy NE, van den Hurk CJG, van den Heuvel MM, Verberkt CA, Becker-Commissaris A, Walraven I, SYMPRO-Lung consortium

doi: 10.1016/S1470-2045(26)00305-0

Genitourinary Cancer

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

Lancet Oncol

Siva S, Ali M, Hardcastle N, Kron T, Higgs B, Foroudi F, Ruben J, Appu S, Martin J, Sridharan S, Montgomery R, Davey R, Lin C, Shaw M, Chander S, Sidhom M, Vanneste BGL, Murphy DG, Lawrentschuk N, Pryor D, Wood S, Moon D, Bressel M

doi: 10.1016/S1470-2045(26)00170-1

Breast Cancer

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer

Lancet Oncol

Kaidar-Person O, Weltens CG, Fortpied C, Scheijmans LJEE, Kirkove CY, Budach V, Peignaux-Casasnovas K, Valli M, Peters M, van der Leij F, Rivera S, Weidner N, van den Bongard DHJG, Linsenmeier C, Abdah-Bortnyak R, Hosni S, Koiter E, Engelen AM, Baten A, Champezou L, Fourquet A, Bartelink HGMM, Struikmans H, Poortmans PMP, EORTC Radiation Oncology and Breast Cancer Groups

doi: 10.1016/S1470-2045(26)00233-0

Lymphoma

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial

Blood

Sharman JP, Laurenti L, Ferrant EF, Casado Montero LF, Mulligan SP, Harrup RA, Opat SS, Ibatici A, Marasca R, Sportoletti P, Thadani-Mulero M, Cazares O, Huang W, Jiang Y, Clark E, Jin HY, Boyer M, Morschhauser F

doi: 10.1182/blood.2025030630

EHA 2026

Leukemia

Related content

CLL13/GAIA: Final 5-year analysis identifies NOTCH1 and EGR2 mutations as independent prognostic factors in venetoclax-treated CLL

CLL14: Final 9-year analysis confirms long-term efficacy of one-year fixed-duration venetoclax plus obinutuzumab in previously untreated CLL

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial

Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes

Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial

LB5001: BRUIN CLL-322: Fixed-duration pirtobrutinib plus venetoclax-rituximab outperforms venetoclax plus rituximab in patients with R/R CLL